FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Hinterhaus Productions
The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease development: how to generate reliable evidence when the number of available patients
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.